This is a working overview of certificate of analysis, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-03-03 and is reviewed periodically as new material appears.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
== History == The company was founded in Bremen on 24 October 1923 as Bremer Flugzeugbau AG by Prof. Henrich Focke, Georg Wulf and Dr. rer. pol. Werner Naumann. Almost immediately, they renamed the company Focke-Wulf Flugzeugbau AG (later Focke-Wulf Flugzeugbau GmbH). Focke-Wulf merged, under government pressure, with Albatros Flugzeugwerke of Berlin in 1931. The Albatros Flugzeugwerke engineer and test pilot Kurt Tank became head of the technical department and started work on the Fw 44 Stieglitz (Goldfinch). Dr Ludwig Roselius became chairman in 1925 and handed over to his brother Friedrich in early 1933. In 1938 Roselius' HAG combine increased its shareholding to 46% and C. Lorenz AG secured 28%. The company was reconstituted as Focke-Wulf Flugzeugbau GmbH and no longer had to publish its accounts. A substantial capital injection occurred at this time. In August 1933 Hans Holle and Rudolf Schubert were given power of attorney over the Berlin branch of Focke-Wulf. Then in October 1933, Focke-Wulf Flugzeugbau A.G. Albatros Berlin was officially registered with the Department of Trade. Dr Roselius always remained the driving force of Focke-Wulf. He and his closest collaborator, Barbara Goette, often met with technical director Professor Kurt Tank. When Roselius died in May 1943, Heinrich Puvogel (later chair of Focke-Wulf) raised 4 million RM and continued handling the financial affairs of Focke-Wulf as chief of Seehandel A.G. Hanna Reitsch demonstrated the Focke-Wulf Fw 61, the first fully controllable helicopter (as opposed to autogyro), in Berlin in 1938.
1. Genetic diversity: Each of the P-450 proteins is unique and accounts (to some extent) for the variation in drug metabolism between individuals. Genetic variations (polymorphism) in P-450 metabolism should be considered when patients exhibit unusual sensitivity or resistance to drug effects at normal doses. Such polymorphism is also responsible for variable drug response among patients of differing ethnic backgrounds.
=== Evolution === Genomic tRNA content is a differentiating feature of genomes among biological domains of life: Archaea present the simplest situation in terms of genomic tRNA content with a uniform number of gene copies, Bacteria have an intermediate situation and Eukarya present the most complex situation. Eukarya present not only more tRNA gene content than the other two kingdoms but also a high variation in gene copy number among different isoacceptors, and this complexity seem to be due to duplications of tRNA genes and changes in anticodon specificity. Evolution of the tRNA gene copy number across different species has been linked to the appearance of specific tRNA modification enzymes (uridine methyltransferases in Bacteria, and adenosine deaminases in Eukarya), which increase the decoding capacity of a given tRNA. As an example, tRNAAla encodes four different tRNA isoacceptors (AGC, UGC, GGC and CGC). In Eukarya, AGC isoacceptors are extremely enriched in gene copy number in comparison to the rest of isoacceptors, and this has been correlated with its A-to-I modification of its wobble base. This same trend has been shown for most amino acids of eukaryal species. Indeed, the effect of these two tRNA modifications is also seen in codon usage bias. Highly expressed genes seem to be enriched in codons that are exclusively using codons that will be decoded by these modified tRNAs, which suggests a possible role of these codons—and consequently of these tRNA modifications—in translation efficiency. Many species have lost specific tRNAs during evolution.
== Personal life == In the early 1990s, Staley enrolled in several rehab programs, but he failed to stay clean for long. At one point, the other members of Alice in Chains flew to Los Angeles for weekly therapy at Staley's rehab. During the Dirt tour, Alice in Chains' manager, Susan Silver, hired bodyguards to keep Staley away from people who might try to pass him drugs, but he ended up relapsing on alcohol and drugs during the tour. Screaming Trees' Mark Lanegan recalled partying with Staley on tour and said that, "off stage, it was an insane, dark, drug and alcohol-fuelled frat party from start to finish, with Layne [Staley] and I raising hell, behaving like teenagers, staying up for days on end. We partook of whatever drugs came our way. Heroin, cocaine, painkillers, anything." Kurt Cobain's death in April 1994 scared Staley into temporary sobriety, but soon he was back into his addiction. Alice in Chains' managers turned down lucrative touring possibilities and kept the band off the road, hoping that would help Staley. Pearl Jam lead guitarist Mike McCready also tried to help Staley by inviting him to his side project, Mad Season. McCready had hoped that playing with sober musicians would encourage Staley. On October 29, 1996, Staley's former fiancée, Demri Lara Parrott, died of a drug overdose. Staley was placed on a 24-hour suicide watch, according to NME, which quoted a friend saying Staley was taking Parrott's death "extremely badly" and had fallen into a deep depression. Lanegan told Rolling Stone in 2002, "He never recovered from Demri's death.
Sources: en.wikipedia.org
The surgeon measures the dimensions (length, width, depth) of the nasal wound, and then delineates them upon the nasal septum, and, if possible, incorporates an additional margin of 3–5 mm of width to the wound measurements; furthermore, the base of the mucosal tissue flap should be at least 1.5-cm wide. The surgeon then makes two parallel incisions along the floor and the roof of the nasal septum; the incisions converge anteriorly, towards the front of the nasal spine. Using an elevator, the flap is dissected in a sub-mucoperichondrial plane. The (far) distal edge of the flap is cut with a right-angle Beaver blade, and then is transposed into the wound. The exposed cartilages will reepithelialise (regenerate the epithelium), provided the opposite (contralateral) side of the septal mucosa is undisturbed. A technical variant of the septal mucosal flap technique is the trap-door flap, which is used to reconstruct one side of the upper half of the nasal lining. It is emplaced in the contralateral nasal cavity, as a superiorly based septal mucosal flap of rectangular shape, like that of a "trap-door". This septomucosal flap variant is a random flap with its pedicle based at the junction of the septum and the lateral nasal skeleton. The surgeon elevates the flap of septal mucosa to the roof of the nasal septum, and then traverses it into the contralateral (opposite) nasal cavity through a slit made by removing a small, narrow portion of the dorsal roof of the septum. Afterwards, the septomucosal flap is stretched across the wound in the mucosal lining of the lateral nose.
=== Malaria === Antimalarial use of the drug has recently (2009) been revived. It simultaneously targets many biological processes in the apicomplexan pathogen though the main mechanism seems to be causing a lethal amount of redox cycling. A 2018 meta-analysis finds that it has proven effective against P. falciparum in Africa. It effectively reduces levels of the transmission-stage gametocyte and has synergy with the standard artemisinin-based combination therapy (ACT). Its effects against other malarial species and P. falciparum populations in other locations are unclear.
Poland's Early Bronze Age began around 2400–2300 BC, whereas its Iron Age commenced c. 750–700 BC. One of the many cultures that have been uncovered, the Lusatian culture, spanned the Bronze and Iron Ages and left notable settlement sites. Around 400 BC, Poland was settled by Celts of the La Tène culture. They were soon followed by emerging cultures with a strong Germanic component, influenced first by the Celts and then by the Roman Empire. The Germanic peoples migrated out of the area by about 500 AD during the great Migration Period of the European Dark Ages. Wooded regions to the north and east were settled by Balts. According to some archaeological research, Slavs have resided in modern Polish territories for only 1,500 years. However, recent genetic studies determined that the inhabitants of Poland are also the descendants of people from before the Migration Period. According to other archaeological and linguistic research, early Slavic peoples were likely present in parts of Poland much earlier, and may have been associated with the ancient Przeworsk culture of the 3rd century BC, though some Slavic groups may have arrived from the east in later periods. The West Slavic and Lechitic peoples as well as any remaining minority clans were organized into tribal units (Polish tribes), as outlined by the anonymous Bavarian Geographer in the 9th century. Largely divided, it was the Western Polans in the Greater Poland region who began a process of unification and created a lasting political structure in the 10th century that subsequently became the state of Poland.[x]
Sources: en.wikipedia.org
Official website Ellen McLain at IMDb Ellen McLain speaking on YouTube, Anime Midwest 2011 convention The VŌC Podcast // Ellen McLain Interview (The voice of GLaDOS, The Administrator, Overwatch) on YouTube
=== Function === PNECs may play a role with chemoreceptors in hypoxia detection. This is best supported by the presence of an oxygen-sensitive potassium channel coupled to an oxygen sensory protein in the rabbit lumenal membrane. They are hypothetically involved in regulating localized epithelial cell growth and regeneration through a paracrine mechanism, whereby their signaling peptides are released into the environment. In addition, they contain neuroactive substances which are released from basal cytoplasm. These substances induce autonomic nerve terminals or vasculature in the deep lamina propria.
== History == The NAFBL was formed in January 1895 and in March 1895, the NAFBL began operation as the third significant U.S. soccer league. It drew its teams primarily from northern New Jersey and New York City. Few records exist for the league, but the teams and standings for four of the five seasons do exist. After its first spring-summer season in 1895, the NAFBL moved to a winter schedule in the fall of 1895. On December 16, 1895, the NAFBL opened its second season with a game pitting the Kearny Scottish-Americans and the International Athletic Club. In 1899, a deep recession, accompanied by the Spanish–American War led to the collapse of several athletic leagues and teams, among them the NAFBL. On August 14, 1906, the league was revived and continued in operation until 1921. That year, several of the top NAFBL teams, frustrated by the amateur/semi-professional nature of the league, joined with other top North Atlantic U.S. teams to form the first fully professional U.S. soccer league, the American Soccer League.
Homocystinuria (HCU) is an inherited disorder of the metabolism of the amino acid methionine due to a deficiency of cystathionine beta synthase or methionine synthase. It is an inherited autosomal recessive trait, which means a child needs to inherit a copy of the defective gene from both parents to be affected. Symptoms of homocystinuria can also be caused by a deficiency of vitamins B6, B12, or folate.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.